ALK-activated Tumors
1 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Phase I Study of LDK378 in Pediatric, Malignancies With a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK) (NCT01742286) | Novartis Pharmaceuticals | 2013-08-28 |
Track ALK-activated Tumors automatically
Every clearance here is in the API, with alerts when new ones post.